gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Carbonyl reductase 3

CBR3, carbonyl reductase 3
Carbonyl reductase 3 catalyzes the reduction of a large number of biologically and pharmacologically active carbonyl compounds to their corresponding alcohols. The enzyme is classified as a monomeric NADPH-dependent oxidoreductase. CBR3 contains three exons spanning 11.2 kilobases and is closely linked to another carbonyl reductase gene - CBR1. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: ACID, CAN, PTEN, HAD, TNS
Papers using CBR3 antibodies
Covalent modification of amino acid nucleophiles by the lipid peroxidation products 4-hydroxy-2-nonenal and 4-oxo-2-nonenal.
Gay Nick, In PLoS ONE, 2001
... A human CBR3 clone was obtained from the MGC clone collection, and a synthetic, codon-adapted CBR1 clone was obtained from GenScript Corporation ...
Papers on CBR3
Risk factors for anthracycline-associated cardiotoxicity.
Lustberg et al., Columbus, United States. In Support Care Cancer, Dec 2015
In pediatric patients, homozygosity for the major allele (G) in the CBR3 gene was associated with increased risk of anthracycline cardiotoxicity.
Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1.
Endo et al., Toyama, Japan. In Org Biomol Chem, Aug 2015
13h also showed high selectivity to CBR1 over its isozyme CBR3 and other enzymes with CBR activity (AKR1B1, AKR1B10, AKR1C1, AKR1C2, AKR1C4, DXCR and DHRS4).
Identification of a functional antioxidant responsive element in the promoter of the Chinese hamster carbonyl reductase 3 (Chcr3) gene.
Terada et al., Tondabayashi, Japan. In Cell Biol Int, Jul 2015
CHCR3, a member of the short-chain dehydrogenase/reductase superfamily, is a carbonyl reductase 3 enzyme in Chinese hamsters.
Carbonyl-reducing enzymes as targets of a drug-immobilised affinity carrier.
Wsól et al., Hradec Králové, Czech Republic. In Chem Biol Interact, Jul 2015
The functionality of the presented carrier was demonstrated with pure recombinant enzymes (AKR1A1, AKR1B1, AKR1B10, AKR1C1, AKR1C2, AKR1C3, AKR1C4, CBR1 and CBR3) as well as with two model biological samples (cell extract from genetically modified Escherichia coli and pre-purified human liver cytosol).
Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3.
Kavanagh et al., Seattle, United States. In Chem Biol Interact, Jul 2015
Little is known about a closely related enzyme, carbonyl reductase 3 (CBR3), which is present in the liver at low basal levels but is highly inducible by the transcription factor Nrf2. Genetic polymorphisms in CBR3, but not CBR1, are associated with differential cardiac outcomes in doxorubicin treated pediatric patients.
Quantitative expression proteomics and phosphoproteomics profile of brain from PINK1 knockout mice: insights into mechanisms of familial Parkinson's disease.
Butterfield et al., Lexington, United States. In J Neurochem, Jun 2015
14-3-3ε, 14-3-3 protein epsilon; 3-PGDH, phosphoglycerate dehydrogenase; ALDOA, aldolase A; APT1, acyl-protein thioesterase 1; CaM, calmodulin; CBR3, carbonyl reductase [NADPH] 3; ENO2, gamma-enolase; HPRT, hypoxanthine-guanine phosphoribosyltransferase; HSP70, heat-shock-related 70 kDa protein 2; IDHc, cytoplasmic isocitrate dehydrogenase [NADP+]; MAPK1, mitogen-activated protein kinase 1; MEK1, MAP kinase kinase 1; MDHc, cytoplasmic malate dehydrogenase; NFM, neurofilament medium polypeptide; NSF, N-ethylmaleimide-sensitive fusion protein; PHB, prohibitin; PINK1, PTEN-induced putative kinase 1; PPIaseA, peptidyl-prolyl cis-trans isomerase A; PSA2, proteasome subunit alpha type-2; TK, transketolase; VDAC-2, voltage-dependent anion-selective channel protein 2.
PTEN functions by recruitment to cytoplasmic vesicles.
Trotman et al., United States. In Mol Cell, May 2015
We demonstrate that the non-catalytic C2 domain of PTEN specifically binds PI(3)P through the CBR3 loop.
Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.
Egle et al., Salzburg, Austria. In Leuk Lymphoma, Feb 2015
Two genotypes of the CBR3 and MLH1 genes affecting the metabolism of cytostatics identified a subgroup with a favorable prognosis (median overall survival not reached vs. 30 months, p=0.01).
Long non-coding RNA UCA1 may be a novel diagnostic and predictive biomarker in plasma for early gastric cancer.
Mu et al., Linyi, China. In Int J Clin Exp Pathol, 2014
The expression levels of 4 lncRNAs: HIF1A-AS1, PVT1, CBR3-AS1 and UCA1 both in tumor and plasma were further confirmed in 20 gastric patients by real-time PCR assay.
The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man.
Wsól et al., Hradec Králové, Czech Republic. In Chem Biol Interact, 2014
The contribution of CBR1 and CBR3 to the reduction of oxcarbazepine was also significant, although their role in oxcarbazepine metabolism in vivo is unclear.
Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.
Blanco et al., Buffalo, United States. In Pharm Res, 2014
METHODS: Cardiac expression of CBR1, CBR3, AKR1A1, AKR1C3 and AKR7A2 was examined by quantitative real time PCR, quantitative immunoblotting, and enzyme activity assays using daunorubicin.
Genetic variation in the carbonyl reductase 3 gene confers risk of type 2 diabetes and insulin resistance: a potential regulator of adipogenesis.
Chuang et al., Taipei, Taiwan. In J Mol Med (berl), 2012
genetic polymorphism in the CBR3 gene conferred risk of type 2 diabetes and insulin resistance in Chinese. The association was probably mediated through modulation of adipogenesis.
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
Bhatia et al., Buffalo, United States. In J Clin Oncol, 2012
CBR3 polymorphisms contribute to increased cardiomyopathy risk associated with anthracycline treatment of childhood cancer.
Proteomic analysis identifies dysfunction in cellular transport, energy, and protein metabolism in different brain regions of atypical frontotemporal lobar degeneration.
Bahn et al., Cambridge, United Kingdom. In J Proteome Res, 2012
A protein encoded by this locus was found to be differentially expressed in postmortem brains from patients with atypical frontotemporal lobar degeneration.
Expression of human carbonyl reductase 3 (CBR3; SDR21C2) is inducible by pro-inflammatory stimuli.
Maser et al., Hradec Králové, Czech Republic. In Biochem Biophys Res Commun, 2012
CBR3 is a novel target gene of inflammatory stimuli; elucidation of its detailed role in inflammation deserves further investigation.
A conserved antioxidant response element (ARE) in the promoter of human carbonyl reductase 3 (CBR3) mediates induction by the master redox switch Nrf2.
Blanco et al., Buffalo, United States. In Biochem Pharmacol, 2012
Computational searches identify a conserved antioxidant response element(ARE) in the distal carbonyl reductase 3 (CBR3) promoter region.
Human carbonyl reductases.
Wsól et al., Hradec Králové, Czech Republic. In Curr Drug Metab, 2010
In the human genome, three SDR genes have been identified to code for the carbonyl reductases CBR1 (SDR21C1), CBR3 (SDR21C2) and CBR4 (SDR45C1).
Pharmacogenetics of target genes across doxorubicin disposition pathway: a review.
Chowbay et al., Singapore, Singapore. In Curr Drug Metab, 2010
This review comprehensively examines the pharmacogenetics of the regulatory nuclear receptor Pregnane-X Receptor (PXR), influx (SLC22A16) and efflux drug transporters (ABCB1, ABCG2, ABCC5, ABCB5 and RLIP76) and drug metabolizing enzymes (CBR1, CBR3) across the biochemical pathway of doxorubicin in Asian breast cancer patients receiving doxorubicin based adjuvant chemotherapy.
Pharmacogenetics in breast cancer therapy.
Wong et al., Singapore, Singapore. In Clin Cancer Res, 2009
For anthracyclines, polymorphisms in genes such as carbonyl reductase 3 (CBR3), ATP-binding cassette subfamily B, member 1 (ABCB1), glutathione-related transporter genes, and oxidative stress-related genes have been reported to correlate with clinical outcomes.
share on facebooktweetadd +1mail to friends